Adaptimmune Therapeutics PLC
NASDAQ:ADAP

Watchlist Manager
Adaptimmune Therapeutics PLC Logo
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Watchlist
Price: 0.2422 USD -4.27% Market Closed
Market Cap: 63.9m USD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one ADAP stock under the Base Case scenario is 1.1782 USD. Compared to the current market price of 0.2422 USD, Adaptimmune Therapeutics PLC is Undervalued by 79%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ADAP Relative Value
Base Case
1.1782 USD
Undervaluation 79%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

0.4
P/S
P/S
Price to Sales
0.4
vs History
96
vs Industry
91
Median 3Y
3.5
Median 5Y
21.1
Industry
7
Forward
1.3
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-2.4
Median 5Y
-3.3
Industry
22.7
Forward
-0.5
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-2.3
Median 5Y
-3.5
Industry
19.4
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-2.7
Median 5Y
-8.9
Industry
22.6
More Details
Negative
P/B
P/B
Price to Book Value
N/A
vs History
vs Industry
62
Median 3Y
3.4
Median 5Y
4.1
Industry
2.6
More Details
0.2
EV/S
EV/S
Enterprise Value to Sales
0.2
vs History
92
vs Industry
41
Median 3Y
1
Median 5Y
9.6
Industry
7.3
Forward
0.6
More Details
3.1
EV/GP
EV/GP
Enterprise Value to Gross Profit
3.1
vs History
3
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9.4
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
15
Median 3Y
-1.1
Median 5Y
-1.6
Industry
4.6
Forward
-0.3
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
14
Median 3Y
-1
Median 5Y
-1.5
Industry
4.5
Forward
-0.2
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
20
Median 3Y
-1
Median 5Y
-1.8
Industry
5
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
16
Median 3Y
-1.1
Median 5Y
-1.9
Industry
3.7
More Details
0.3
EV/IC
EV/IC
Enterprise Value to IC
0.3
vs History
88
vs Industry
52
Median 3Y
0.9
Median 5Y
1.8
Industry
4.9
More Details

Multiples Across Competitors

ADAP Competitors Multiples
Adaptimmune Therapeutics PLC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
UK
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
63.9m USD 0.4 -0.9 -0.8 -0.6
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 913 071.5 -161 183.8 -195 728.5 -193 495.1
US
Abbvie Inc
NYSE:ABBV
329.9B USD 5.8 79.4 15.1 22.4
US
Amgen Inc
NASDAQ:AMGN
150.1B USD 4.4 25.3 13.8 22.7
US
Gilead Sciences Inc
NASDAQ:GILD
134B USD 4.7 22.5 9.8 13.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
113.9B USD 10.3 -115.2 24.5 25.6
US
Epizyme Inc
F:EPE
94.1B EUR 2 077.3 -530.1 -577.2 -561.8
AU
CSL Ltd
ASX:CSL
114.1B AUD 4.9 27.2 16.8 21
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
56.4B USD 4 12.5 11.1 12.5
US
Seagen Inc
F:SGT
39.3B EUR 20 -61.4 -66.1 -59.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
41.5B USD 17.7 -153.8 -689.5 -345.5
P/E Multiple
Earnings Growth PEG
UK
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Average P/E: 33.4
Negative Multiple: -0.9 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 183.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
79.4
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
25.3
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
22.5
188%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -115.2 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -530.1 N/A N/A
AU
CSL Ltd
ASX:CSL
27.2
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.5
7%
1.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.4 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -153.8 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
UK
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Average EV/EBITDA: 15.2
Negative Multiple: -0.8 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 728.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.1
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
13.8
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
9.8
6%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.5
17%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -577.2 N/A N/A
AU
CSL Ltd
ASX:CSL
16.8
11%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.1
11%
1
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.1 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -689.5 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
UK
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Average EV/EBIT: 19.6
Negative Multiple: -0.6 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -193 495.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.4
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
22.7
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.5
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.6
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -561.8 N/A N/A
AU
CSL Ltd
ASX:CSL
21
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.5
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.7 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -345.5 N/A N/A

See Also

Summary
ADAP intrinsic value, competitors valuation, and company profile.
DCF Valuation
ADAP stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ADAP stock valuation using valuation multiples.
Wall Street Estimates
ADAP price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ADAP stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 264,100+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.